Szczepionka firmy Johnson & Johnson

EN_01465806_1177

30,00 EUR Private use
Making print for private purpose, storage in computer memory, no distribution rights.
40,00 EUR Internet - private use
Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
75,00 EUR Internet commercial use
Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
90,00 EUR Print use
Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices

caption

(FILES) In this file photo taken on August 28, 2019 an entry sign to the Johnson & Johnson campus shows their logo in Irvine, California. - The Johnson & Johnson vaccine is highly effective against severe Covid-19, including against the South African and Brazil variants, new documents released by the US Food and Drug Administration showed on February 24, 2021. In large clinical trials, the vaccine efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil. (Photo by Mark RALSTON / AFP)

headline Szczepionka firmy Johnson & Johnson

created date 2019-08-28

credit MARK RALSTON/AFP/East News

source AFP

byline MARK RALSTON

original transmission reference AFP_93P37U

weight 2,51MB

size 43cm x 28cm by 300dpi

keywords - Show

2019, 2021, 24, 28, 6, 7, 81, 85, 87, 9, ADMINISTRATION, AFRICA, AFRICAN, AGAINST, AN, AND, AUGUST, BRAZIL, BY, CALIFORNIA, CAMPUS, CLINICAL, COVID-19, DISEASE, DOCUMENTS, DRUG, EFFECTIVE, EFFICACY, ENTRY, FEBRUARY, FILE, FILES, FOOD, HEALTH, HIGHLY, HORIZONTAL, ILLUSTRATION, IN, INCLUDING, INDUSTRY, IRVINE, IS, JOHNSON, LARGE, LOGO, MARK, NEW, ON, PERCENT, PHARMACEUTICAL, RALSTON, RELEASED, SEVERE, SHOWED, SHOWS, SIGN, SOUTH, STATES, TAKEN, THE, THEIR, THIS, TO, TRIALS, UNITED, US, VACCINE, VARIANTS, WAS,